Sarepta Therapeutics, Inc. SRPT
We take great care to ensure that the data presented and summarized in this overview for Sarepta Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SRPT
View all-
Black Rock Inc. New York, NY10.3MShares$1.34 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.04MShares$1.18 Billion0.03% of portfolio
-
Capital International Investors Los Angeles, CA4.32MShares$563 Million0.14% of portfolio
-
State Street Corp Boston, MA4.14MShares$539 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X03.82MShares$497 Million0.33% of portfolio
-
Avoro Capital Advisors LLC New York, NY3MShares$391 Million6.47% of portfolio
-
Morgan Stanley New York, NY2.62MShares$342 Million0.03% of portfolio
-
Farallon Capital Management LLC San Francisco, CA2.3MShares$299 Million1.75% of portfolio
-
Wellington Management Group LLP Boston, MA2.06MShares$268 Million0.06% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD1.96MShares$255 Million0.2% of portfolio
Latest Institutional Activity in SRPT
Top Purchases
Top Sells
About SRPT
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at SRPT
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 12
2024
|
Deirdre P Connelly |
BUY
Grant, award, or other acquisition
|
Direct |
2,842
+50.0%
|
-
|
Sep 04
2024
|
M Kathleen Behrens |
SELL
Bona fide gift
|
Direct |
746
-0.39%
|
-
|
Aug 30
2024
|
Ian Michael Estepan Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,985
-14.99%
|
$819,945
$137.36 P/Share
|
Aug 16
2024
|
Michael Andrew Chambers |
BUY
Open market or private purchase
|
Indirect |
37,038
+4.3%
|
$4,926,054
$133.93 P/Share
|
Jul 03
2024
|
M Kathleen Behrens |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+7.25%
|
$195,000
$13.9 P/Share
|
Jun 25
2024
|
Bilal Arif Chief Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
3,898
-18.33%
|
$635,374
$163.23 P/Share
|
Jun 25
2024
|
Ryan Edward Brown EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
38,957
-14.51%
|
$6,272,077
$161.43 P/Share
|
Jun 25
2024
|
Ryan Edward Brown EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
23,500
+29.53%
|
$1,457,000
$62.77 P/Share
|
Jun 24
2024
|
Bilal Arif Chief Tech Ops Officer |
SELL
Open market or private sale
|
Direct |
7,859
-5.84%
|
$1,288,876
$164.8 P/Share
|
Jun 24
2024
|
Bilal Arif Chief Tech Ops Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,352
-7.47%
|
$385,728
$164.64 P/Share
|
Jun 24
2024
|
Ian Michael Estepan Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,483
-5.85%
|
$407,212
$164.64 P/Share
|
Jun 24
2024
|
Dallan Murray Chief Customer Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,352
-9.65%
|
$385,728
$164.64 P/Share
|
Jun 24
2024
|
Louise Rodino Klapac Head of R&D, CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,182
-2.94%
|
$357,848
$164.64 P/Share
|
Jun 24
2024
|
Ryan Edward Brown EVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,352
-6.73%
|
$385,728
$164.64 P/Share
|
Jun 21
2024
|
Bilal Arif Chief Tech Ops Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+16.57%
|
-
|
Jun 21
2024
|
Ian Michael Estepan Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+12.84%
|
-
|
Jun 21
2024
|
Dallan Murray Chief Customer Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+20.41%
|
-
|
Jun 21
2024
|
Louise Rodino Klapac Head of R&D, CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+7.76%
|
-
|
Jun 21
2024
|
Ryan Edward Brown EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,250
+15.17%
|
-
|
May 02
2024
|
Dallan Murray Chief Customer Officer |
SELL
Open market or private sale
|
Direct |
3,635
-16.71%
|
$508,900
$140.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 39.8K shares |
---|---|
Exercise of conversion of derivative security | 99.8K shares |
Open market or private purchase | 112K shares |
Open market or private sale | 84.4K shares |
---|---|
Bona fide gift | 746 shares |
Payment of exercise price or tax liability | 32.4K shares |